| Reference | </br>1:Radiotherapy quality assurance of the IAEA-HypoX trial of the accelerated radiotherapy in the treatment of head and neck squamous cell carcinoma with or without the hypoxic radiosensitizer nimorazole. Hassan Metwally MA, Ali R, Kuddu M, Shouman T, Strojan P, Overgaard J, Grau C.Acta Oncol. 2015;54(9):1673-7. doi: 10.3109/0284186X.2015.1074721. Epub 2015 Sep 23. No abstract available. PMID: 26397148 </br>2:Photoelectron Spectra and Electronic Structures of the Radiosensitizer Nimorazole and Related Compounds. Feketeová L, Plekan O, Goonewardane M, Ahmed M, Albright AL, White J, O/’Hair RA, Horsman MR, Wang F, Prince KC.J Phys Chem A. 2015 Oct 1;119(39):9986-95. doi: 10.1021/acs.jpca.5b05950. Epub 2015 Sep 18. PMID: 26344652 </br>3:IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma. Hassan Metwally MA, Ali R, Kuddu M, Shouman T, Strojan P, Iqbal K, Prasad R, Grau C, Overgaard J.Radiother Oncol. 2015 Jul;116(1):15-20. doi: 10.1016/j.radonc.2015.04.005. Epub 2015 Apr 22. PMID: 25913070 </br>4:A rapid and sensitive determination of hypoxic radiosensitizer agent nimorazole in rat plasma by LC-MS/MS and its application to a pharmacokinetic study. Das S, Dubey R, Roychowdhury S, Ghosh M, Sinha BN, Kumar Pradhan K, Bal T, Muthukrishnan V, Seijas JA, Pujarid A.Biomed Chromatogr. 2015 Oct;29(10):1575-80. doi: 10.1002/bmc.3461. Epub 2015 Apr 5. PMID: 25845449 </br>5:Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study. Bentzen J, Toustrup K, Eriksen JG, Primdahl H, Andersen LJ, Overgaard J.Acta Oncol. 2015 Jul;54(7):1001-7. doi: 10.3109/0284186X.2014.992547. Epub 2015 Jan 28. PMID: 25629651 </br>6:Predictive value of (18)F-FAZA PET imaging for guiding the association of radiotherapy with nimorazole: a preclinical study. Tran LB, Bol A, Labar D, Cao-Pham TT, Jordan B, Grégoire V, Gallez B.Radiother Oncol. 2015 Feb;114(2):189-94. doi: 10.1016/j.radonc.2014.12.015. Epub 2015 Jan 20. PMID: 25616539 </br>7:Study of the population pharmacokinetic characteristics of nimorazole in head and neck cancer patients treated in the DAHANCA-5 trial. Hassan Metwally MA, Jansen JA, Overgaard J.Clin Oncol (R Coll Radiol). 2015 Mar;27(3):168-75. doi: 10.1016/j.clon.2014.11.024. Epub 2014 Dec 16. PMID: 25530485 </br>8:NIMRAD – a phase III trial to investigate the use of nimorazole hypoxia modification with intensity-modulated radiotherapy in head and neck cancer. Thomson D, Yang H, Baines H, Miles E, Bolton S, West C, Slevin N.Clin Oncol (R Coll Radiol). 2014 Jun;26(6):344-7. doi: 10.1016/j.clon.2014.03.003. Epub 2014 Mar 28. No abstract available. PMID: 24685344 </br>9:Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC). Metwally MA, Frederiksen KD, Overgaard J.Acta Oncol. 2014 May;53(5):654-61. doi: 10.3109/0284186X.2013.864050. Epub 2013 Dec 13. PMID: 24328536 </br>10:Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Toustrup K, Sørensen BS, Lassen P, Wiuf C, Alsner J, Overgaard J; Danish Head and Neck Cancer Group (DAHANCA)..Radiother Oncol. 2012 Jan;102(1):122-9. doi: 10.1016/j.radonc.2011.09.010. Epub 2011 Oct 11. PMID: 21996521
|
